John Griffin
Internal Medicine · Greensboro, NCNPI 1689753923
Payments from drug & device makers
Across 76 payments — averaging $15.14 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$202
- Amgen$133
- Novartis$124
- AstraZeneca$98
- Boehringer Ingelheim$90
- Pfizer$68
- plus $437 from 13 others
What the payments were for
- Food & beverage$1,13999%
- Education$121%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 14 | $202 |
| Amgen | 9 | $133 |
| Novartis | 8 | $124 |
| AstraZeneca | 7 | $98 |
| Boehringer Ingelheim | 6 | $90 |
| Pfizer | 4 | $68 |
| Novo Nordisk | 4 | $59 |
| Merck | 4 | $55 |
| Sanofi-aventis U.S. LLC | 3 | $40 |
| Sumitomo Pharma America, Inc. | 2 | $39 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Biohaven Pharmaceuticals, Inc. | 2 | $34 |
| Almatica Pharma LLC | 1 | $33 |
| Johnson & Johnson | 2 | $30 |
| Amarin Pharma, Inc. | 2 | $30 |
| AbbVie | 2 | $29 |
| Eisai Inc. | 2 | $27 |
| Xeris Pharmaceuticals, Inc. | 1 | $14 |
| Esperion Therapeutics, Inc. | 1 | $12 |
How this compares
$1,151 in reported general payments places this provider in the 75th percentile of 3,302 internal medicine providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 36 | $41,343 |
| TrulicityDulaglutide | 28 | $35,984 |
| JardianceEmpagliflozin | 25 | $25,027 |
| XareltoRivaroxaban | 17 | $21,190 |
| OzempicSemaglutide | 11 | $10,454 |
| Telmisartan | 65 | $2,738 |
| Atorvastatin Calcium | 189 | $1,890 |
| Rosuvastatin Calcium | 130 | $1,770 |
| Amlodipine-ValsartanAmlodipine Besylate/Valsartan | 32 | $1,648 |
| Amlodipine Besylate | 174 | $1,111 |
| Omeprazole | 34 | $839 |
| Levothyroxine Sodium | 66 | $827 |
| Gabapentin | 51 | $793 |
| Pantoprazole Sodium | 48 | $673 |
| Bupropion XlBupropion Hcl | 26 | $659 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $68 | $41,34336 claims |
| Lilly USA, LLCTrulicity | $202 | $35,98428 claims |
| Boehringer IngelheimJardiance | $90 | $25,02725 claims |
| Johnson & JohnsonXarelto | $30 | $21,19017 claims |
| Novo NordiskOzempic | $59 | $10,45411 claims |
| Almatica Pharma LLCSertraline Hcl | $33 | $26638 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,302 internal medicine providers in North Carolina.
Other internal medicine in Greensboro
- Keung LeeGreensboro$5.1M
- Walter PharrGreensboro$2.3M
- Manesh PatelDurham$27.2M
- Saad UsmaniCharlotte$16.2M
- Christina KennellyCharlotte$15.4M
- John RubinoRaleigh$13M
- Adam DevoreDurham$11.8M
- Krishnakumar UdayakumarDurham$11M
- Sylvia ShoffnerCary$7.1M
- Wayne HarperRaleigh$6.7M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.